bluebird bio’s (BLUE) “Neutral” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of bluebird bio (NASDAQ:BLUE) in a report published on Monday, Benzinga reports. Cantor Fitzgerald also issued estimates for bluebird bio’s FY2024 earnings at ($1.31) EPS.

Several other research firms have also weighed in on BLUE. Royal Bank of Canada reiterated a sector perform rating and issued a $4.00 price objective on shares of bluebird bio in a research note on Thursday, August 15th. JPMorgan Chase & Co. lowered shares of bluebird bio from an overweight rating to a neutral rating in a research note on Thursday, August 15th. Bank of America dropped their price objective on shares of bluebird bio from $4.00 to $3.00 and set a buy rating on the stock in a research note on Thursday, August 15th. Robert W. Baird dropped their price objective on shares of bluebird bio from $7.00 to $6.00 and set an outperform rating on the stock in a research note on Thursday, August 15th. Finally, Barclays dropped their price target on shares of bluebird bio from $8.00 to $4.00 and set an overweight rating on the stock in a research note on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and an average target price of $4.74.

bluebird bio Price Performance

BLUE stock opened at $0.49 on Monday. The firm has a market capitalization of $53.79 million, a P/E ratio of -0.66 and a beta of 0.75. The company’s 50 day simple moving average is $0.85 and its 200-day simple moving average is $1.00. bluebird bio has a 52-week low of $0.48 and a 52-week high of $5.53.

Hedge Funds Weigh In On bluebird bio

A number of institutional investors have recently made changes to their positions in BLUE. Ghisallo Capital Management LLC bought a new position in shares of bluebird bio in the fourth quarter worth about $4,347,000. Vestal Point Capital LP bought a new position in bluebird bio during the fourth quarter valued at about $2,967,000. Vanguard Group Inc. increased its stake in bluebird bio by 19.6% during the first quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock valued at $13,438,000 after acquiring an additional 1,723,081 shares during the period. HBK Investments L P bought a new position in bluebird bio during the fourth quarter valued at about $2,070,000. Finally, AQR Capital Management LLC increased its stake in bluebird bio by 315.3% during the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock valued at $1,223,000 after acquiring an additional 1,013,144 shares during the period. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.